Immunocore Ltd raises US$130m in Series B round
With the financing led by General Atlantic, the British company wants to expand a novel platform and advance its ImmTAX pipeline to the clinic.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1461 entries already.
Entries by Thomas Gabrielczyk
Vitamin C may boost checkpoint inhibitor efficacy
/in News/by Thomas GabrielczykHigh amounts of injected vitamin C may delay the growth of many types of tumours and boost the anticancer power of immune checkpoint therapies, report Italian oncologists.
Roche grabs Bicycle Therapeutics platform
/in News/by Thomas GabrielczykRoche AGs has paid US$30m upfront in a potential US$1.7bn deal to get access to Bicycle Therapeutics plcs technology platform to target immune checkpoints.
Microglia inhibitor stops neuronal cell death after TBI
/in News/by Thomas GabrielczykResearchers at Trinity College in Dublin have demonstrated that resetting brain-specific immune cells improves traumatic brain injury (TBI) recovery.
Post-Brexit budget drives cuts in Horizon Europe
/in News/by Thomas GabrielczykNegotiations of the EU Council on the EU’s seven-year budget have failed, putting R&D funding at risk for significant cuts.
Royal DSM acquires Glycom A/S for 765m
/in News/by Thomas GabrielczykRoyal DSM NV has entered the growing market of human milk oligosaccharides (HMO) taking over the producer of recombinant 2-fucosyl lactose, Danish Glycom A/S.
Immatics Biotechnologies lands 1.1bn deal with GSK
/in News/by Thomas GabrielczykUS-German immunooncology specialist Immatics Biotechnologies GmbH has licensed two of its TCR-T programs to GlaxoSmithKline for US$50m upfront.
KKR backs Belgian tech provider Univercells SA
/in News/by Thomas GabrielczykUnivercells S.A. cashes in up to 50m from the KKR subsidiary Gamma Bioscience to advance its gene and cell therapy manufacturing platform.
EU diagnostic labs prepared for Sars-CoV-2
/in News/by Thomas GabrielczykShortly before a EU health ministers discuss the spread of the Chinese coronavirus, EU diagnostic labs have considered themselves prepared for a possible Sars-CoV-2 epidemic.
PharmaMar/Jazz Pharmaceuticals get NDA priority for lung cancer drug
/in News/by Thomas GabrielczykPharmaMar and Jazz Pharmaceuticals have received FDA Priority Review of a NDA for lurbinectedin in relapsed SCLC (Small Cell Lung Cancer).